Aspirin does not Affect the Hematoma Volume and Growth in Severe Spontaneous Intracranial Hematoma

doi:10.21203/rs.3.rs-513591/v1

PDF

Research Article

Aspirin does not Affect the Hematoma Volume and Growth in Severe Spontaneous Intracranial Hematoma

https://doi.org/10.21203/rs.3.rs-513591/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 13 Oct, 2021

Read the published version in Neurosurgical Review →

You are reading this latest preprint version

Baseline hematoma volume (HV) and hematoma growth (HG) affect the prognosis of spontaneous intracranial hematoma (ICH), but there is still a lack of evidence on the effects of aspirin (acetylsalicylic acid, ASA) on HV and HG in patients with severe ICH. This study retrospectively analyzed patients with severe ICH who met the inclusion and exclusion criterias in Beijing Tiantan Hospital, Capital Medical University between January 1, 2015 and July 31, 2019. Severe ICH patients were divided into ASA group and nASA group according to ASA usage, and the effects of prior ASA on HV and HG were evaluated respectively. And possible risk factors for HG were screened. Totally, 221 patients with severe ICH were consecutively enrolled into this study. There were 72 (32.58%) patients in ASA group and 149 patients (67.42%) in nASA group. Although the baseline HV of the nASA group was significantly higher than that of the ASA group (45.51±29.76 VS 32.67±25.85, p=0.001), after adjusting for confounding factors, the prior ASA did not significantly affect the baseline HV (p = 0.057). Similarly, although the incidence of HG in nASA group was higher than that in ASA group (36.2% VS 25.0%, p = 0.095), ASA did not significantly affect the occurrence of HG (p =0.057). In addition, we found that admission high blood pressure and GCS were risk factors for HG. Prior ASA does not increase the baseline HV and the incidence of HG in severe ICH patients. In addition, admission high blood pressure and GCS were risk factors for HG.

Neurosurgery

Aspirin

Antiplatelet

Intracerebral hemorrhage

Hematoma expansion

Stroke.

Spontaneous intracranial hemorrhage (ICH) has a poor outcome than ischemic stroke[1,2], especially severe ICH which usually leads to severe disability or death[3,4]. According to researches, hematoma growth (HG) after the onset of ICH was an important poor prognostic factor.[5–7]

Aspirin (acetylsalicylic acid, ASA) is the most widely used antiplatelet drug. Its efficacy has been proven in primary and secondary stroke prevention.[8,9] However, the effective inhibition of platelet function by ASA may adversely affect certain bleeding disorders.[10–12] With the increasing population of receiving prior ASA at the time of ICH onset, the impact of prior ASA on hematoma volume (HV) and HG in ICH patients has aroused discussion among researchers.[13] Although some observational studies[14–16] have analyzed the effects of prior ASA on HV and HG before, there is still no consensus yet. Evidence in this area is still scarce, especially for patients with severe ICH.

Therefore, we designed a retrospective cohort study to explore the effects of prior ASA on HV and HG in severe ICH patients.

This retrospective study was approved by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University (reference number: KY2019-096-02).

Study Population

Severe ICH patients admitted to Beijing Tiantan Hospital, Capital Medical University between January 1, 2015 and July 31, 2019 were continuously enrolled into this study referred to the inclusion and exclusion criteria. The informed consent had all been signed by enrolled patients or their family members.

Inclusion and Exclusion Criteria

Inclusion criteria: (i) patients were diagnosed with severe ICH; (ii) patients were older than 18 years.

Exclusion criteria: (i) sever ICH was caused by aneurysm, moyamoya disease, vascular malformation, tumor, cerebral venous thrombosis or hemorrhagic transformation of ischemic infarction; (ii) patients were with hereditary coagulopathy; (iii) patients were with coagulation dysfunction attributed to malignant tumor, liver or renal dysfunction; (iv) patients taken other antiplatelet drugs other than only ASA or receiving anticoagulant therapy (such as, vitamin K antagonist (Warfarin), dabigatran or rivaroxaban) in 7 days; (v) The time from onset of symptoms to admission computed tomography (CT) was more than 24 hours.

Data Collection

Severe ICH patients’ baseline characteristics were collected from the electronic medical records of Beijing Tiantan Hospital, Capital Medical University. Including (i) demographic characteristics: age, gender; (ii) vascular risk factors: smoking, alcohol, admission high blood pressure, admission low blood pressure; (iii) medical history: hypertension, diabetes, coronary heart disease, ischemic stroke history, cerebral hemorrhage history, history of ASA; (iv) radiographic characteristics of admission CT and follow-up CT in 6 days after ICH onset; (v) functional status: admission Glasgow Coma Scale (GCS).

The admission CT was regarded as baseline CT and the follow-up CT was regarded as control CT. All patients' CT was analyzed by two independent neurosurgeons who were blinded to the clinical and anamnestic histories. The following data was collected from the admission CT: (i) hemorrhage side；(ii) hemorrhage localization; hemorrhage localization was divided into shallow and deep. When hemorrhage was located in basal ganglia, thalamus, internal capsule, cerebellum and brainstem, it was defined as deep; when IH was located in other areas, it was defined as shallow. (iii) whether combined with ventricular hematoma; (iv) whether combined with subarachnoid hemorrhage; (v) whether combined with hydrocephalus; (vi) whether combined with blend sign;[17] (vii) whether combined with black hole sign;[18] (viii) whether combined with satellite sign;[19] (ix) whether combined with irregular shape;[20] (x) whether combined with heterogeneous hematoma density[20]; (xi) HV (mL, including intraventricular hematoma); HV was measured by accumulating the product of slice thickness multiplied by the hematoma area of each CT slice with hematoma. The hematoma area of each CT slice was automatically measured by CT software (Neusoft PACS/RIS version 5.5.5.70613) after manually sketching the range of the hematoma. HV change was calculated by subtracting the baseline HV from the ICH volume on the control CT scan.

Definition and outcomes

Severe ICH was defined as supratentorial hematoma volume >30ml, infratentorial hematoma volume >10ml or midline shift >1cm.[4]

Prior ASA was defined as taking ASA continuously for more than 7 days before the onset of ICH and the interruption time less than 7 days. [4,21,22]

HG was defined as a proportional increase ≥ 33% or an absolute HV increase ≥ 6 mL at any control CT scan in 6 days after ICH onset.[23]

Statistical Analysis

In this study, all statistical methods were done by SPSS statistical software (IBM, version 26). In groups comparison, categorical variables were analyzed by chi-square test or Fisher exact test and continuous variables were analyzed by Mann-Whitney U test. Regression analysis was used to adjusted for confounding variables. Univariate analysis was used to analyze the relationship between variables and HG; multivariate logistics regression analysis was used to screen risk factors for HG. Two-side p value ＜ 0.05 was considered statistically significant.

Study population

Totally, 1548 adult patients were diagnosed with ICH between January 1, 2015 and July 31, 2019 in Beijing Tiantan Hospital, Capital Medical University; 354 patients were excluded due to a diagnosis of aneurysm, arteriovenous malformation, or moyamoya disease etc.; 883 patients were excluded because they were not severe ICH; 43 patients were excluded because the time from the onset of ICH to their first CT scan was more than 24 hours; 27 patients were excluded because they took other antiplatelet or drugs (such as, vitamin K antagonist (Warfarin), clopidogrel) in 7 days; 9 patients were excluded because they were accompanied by coagulopathy, liver or kidney dysfunction; 11 patients were excluded duo to missing data. Finally, 221sever ICH patients were consecutively enrolled into this study.

ASA Prevalence and Characteristics

There were 50 females and 171 males in this study. Among the study population, there were 72 (32.58%) patients taking ASA within 7 days before sever ICH onset. According to ASA usage, the study population were divided into the ASA group and the nASA group. Their baseline characteristics were summarized in table 1. Compared with nASA group, patients in ASA group were older and more likely to develop diabetes, coronary heart disease, ischemic stroke, and cerebral hemorrhage. There was no significant statistical difference in other variables between nASA group and ASA group.

Association between prior ASA and HV, HG

The results of analysis patients' admission CT showed baseline HV (45.51±29.76) of severe ICH patients in nASA group was significantly higher than that (32.67±25.85) of ASA group (p = 0.001), as shown in table 2. However, after adjusting for factors of age, diabetes, coronary heart disease, ischemic stroke, cerebral hemorrhage and hydrocephalus, the impact of ASA on baseline HV did not reach statistical differences (p =0.057, 95% confidence interval (CI), -10.042 (-20.376, 0.292)), as shown in table 3.

Table 2 showed although the statistical difference was not reached, the ratio (54/149, 36.2%) of HG in nASA group was higher than that (18/72, 25.0%) in ASA group. Similarly, after adjusting for factors of age, diabetes, coronary heart disease, ischemic stroke, cerebral hemorrhage and hydrocephalus, ASA did not significantly affect HG of sever ICH patients (p =0.057, 95% CI, -10.042 (-20.376, 0.292)), as shown in table 3.

Risk Factors of HG

The study population were divided into HG group and nHG group according to the change of HV; their characteristics were summarized in table 4. In univariate analysis, HG were significantly correlated with admission high blood pressure, hydrocephalus, HV and GCS (p＜0.05), as shown in table 4.

To screen risk factors of HG, variables with p＜0.1 in univariate analysis (shown in table 4) were included into multivariate analysis. After adjusting for factors of admission high blood pressure, coronary heart disease, ASA, hydrocephalus, HV and GCS, the predictive indicators of HG were admission high blood pressure and GCS, as shown in table 5.

In the current study, we retrospectively evaluated the effects of prior ASA on HV and HG in severe ICH patients. As demonstrated here, prior ASA did not significantly affect the baseline HV and HG in severe ICH patients, which was consistent with the results of previous reports[24,25]. Besides, the results showed admission high blood pressure and GCS were risk factors for HG in severe ICH patients.

Previous studies were conflicting in assessing the effects of ASA on HV and HG. In 2016, a prospective study and meta-analysis showed that prior antiplatelet therapy (APT) increased the baseline HV and increased the risk of HG in ICH patients.[16] In addition, a systematic review of more than 5000 ICH patients also showed APT was an independent predictor of HG.[26] Yet, these two studies had a selection bias in their enrolled population and their result may have certain limitations. Otherwise, increasing evidences suggested APT had no significant effect on baseline HV and HG in ICH patients.[24,25] In 2018, Verena van Ginneken et al. did not find significant effects of APT on baseline HV (p = 0.32) or HG (OR 0.8, 95% CI 0.4-1.9).[25] Our conclusions consistent with that. Recently, a study about effects of ASA on cerebral hemorrhage in mice also suggested the application of ASA did not increase the size of cerebral hemorrhage in mice.[27] Moreover, although combination APT was associated with a poor prognosis, single APT did not affect the prognosis of ICH patients, according to reports.[28] These evidences showed that prior ASA is safe in ICH patients.

Unlike current study, Michael Moussouttas et al. found although there was no statistical significance, ICH patients receiving prior APT had a greater absolute HV and a higher proportion of HG compared with that not receiving prior APT.[24] In current study, the baseline HV of sever ICH patients in ASA group was significantly smaller than that in nASA group and the ratio of HG in ASA group was lower than that in nASA group. The underlying reasons of this difference may be the HV calculation method or the APT withdrawal effect. Previous studies[14,15,26,29] mostly used A×B×C/2 method [30]to calculate HV. Although this method has high sensitivity and specificity when measuring cerebral parenchymal hematoma, its accuracy will be reduced when measuring intraventricular HV.[30] In this study, intraventricular hematoma was included in total HV, which may be related to the above difference. According to reports, studies have shown that the sudden withdrawal of APT may increase the sensitivity of platelets to some stimuli, thereby enhancing blood coagulation and preventing further bleeding after the occurrence of ICH.[31] Recently, Santosh Murthy et al.[14] and Maximilian I. Sprügel et al.[32] also observed similar results, although they did not provide a reasonable explanation for it.

HG is associated with mortality of ICH patients[7] and effective control of risk factors for HG may reduce its occurrence. Previous studies have reported some independent risk factors for HG, such as low hemoglobin[33], serum magnesium level[34], spot sign[6] etc.. As current study showed admission high blood pressure and GCS were also risk factors for HG in severe ICH patients. These findings were consistent with results of previous researches[1,26,35]. Particularly, admission high blood pressure was critical to the outcome of ICH patients. A large number of prospective studies have demonstrated that effectively reducing hypertension can significantly improve the prognosis of ICH patients.[36–38] It is worth noting that some special signs such as blend sign[17], black hole sign[41], satellite sign[42], hematoma shape and density[20] etc.of non-enhanced CT can be used as reliable risk factors for HG, which has attracted the attention of researchers. [39,40] Unfortunately, no similar differences were observed between HG and nHG groups in this study population. The reason for this may be that non-severe ICH patients were excluded in this study, thereby reducing the difference between the two groups. According to reports, early HG mainly occurred within the first 7 to 8 hours after the onset of ICH. It is reported that early HG mainly occurred within the first 7 to 8 hours after the onset of ICH[43], our study extended the time to receive CT to hospital to 24 hours. This means that some ICH patients in this study already had HG before they received CT in the hospital, which may also reduce the difference between the two groups.

This study has several advantages. The population only included patients with severe ICH, which can better reflect the effects of ASA on severe ICH. Besides, our study excluded ICH patients taking anticoagulant drugs and antiplatelet drugs other than aspirin, thereby avoiding the influence of other drugs on the results of the study. This research also has some shortcomings. The time of occurrence of HG was not included in the analysis. In addition, our study is a single-center retrospective study, which has certain limitations.

In conclusion, prior ASA does not increase the baseline HV and the incidence of HG in severe[] ICH patients. Admission high blood pressure and GCS were risk factors for HG.

Conflicts of Interest

Authors declare no conflicts of interest.

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (reference number: KY2019-096-02).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

The participant has consented to the submission of the results.

Authors' contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Junhua Yang, Kaiwen Wang and Shaohua Mo. The first draft of the manuscript was written by Junghua Yang, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Statement

This study is supported by two projects: National Natural Science Foundation of China (Grant No. 81471210 and 81671129) and Major special projects in the 13th five-year plan (Grant No.2016YFC1301800).

Acknowledgment

We gratefully thank the two neurosurgeons who provided CT analysis, and thanks to the all the patients who were enrolled in the study.

Al-Shahi Salman R, Frantzias J, Lee RJ, Lyden PD, Battey TWK, Ayres AM, Goldstein JN, Mayer SA, Steiner T, Wang X, Arima H, Hasegawa H, Oishi M, Godoy DA, Masotti L, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Jang D-K, Davalos A, Castillo J, Yao X, Claassen J, Volbers B, Kazui S, Okada Y, Fujimoto S, Toyoda K, Li Q, Khoury J, Delgado P, Sabín JÁ, Hernández-Guillamon M, Prats-Sánchez L, Cai C, Kate MP, McCourt R, Venkatasubramanian C, Diringer MN, Ikeda Y, Worthmann H, Ziai WC, d’Esterre CD, Aviv RI, Raab P, Murai Y, Zazulia AR, Butcher KS, Seyedsaadat SM, Grotta JC, Martí-Fàbregas J, Montaner J, Broderick J, Yamamoto H, Staykov D, Connolly ES, Selim M, Leira R, Moon BH, Demchuk AM, Di Napoli M, Fujii Y, Anderson CS, Rosand J, Hanley DF, Butcher KS, Davis S, Gregson B, Lees KR, Lyden PD, Mayer SA, Muir KW, Steiner T, Xie P, Bakhshayesh B, McDonald M, Brott T, Pennati P, Parry-Jones AR, Smith CJ, Hopkins SJ, Slevin M, Campi V, Singh P, Papa F, Popa-Wagner A, Tudorica V, Takagi R, Teramoto A, Weissenborn K, Lanfermann H (2018) Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. The Lancet Neurology 17:885–894. doi: 10/gfcpqz
An SJ, Kim TJ, Yoon B-W (2017) Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke 19:3–10. doi: 10/f9pvvm
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860. doi: 10.1016/S0140-6736(09)60503-1
van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. The Lancet Neurology 9:167–176. doi: 10.1016/S1474-4422(09)70340-0
Barletta JF, Abdul-Rahman D, Hall ST, Mangram AJ, Dzandu JK, Frontera JA, Zach V (2020) The Role of Desmopressin on Hematoma Expansion in Patients with Mild Traumatic Brain Injury Prescribed Pre-injury Antiplatelet Medications. Neurocrit Care 33:405–413. doi: 10/ghsctx
Barras CD, Tress BM, Christensen S, MacGregor L, Collins M, Desmond PM, Skolnick BE, Mayer SA, Broderick JP, Diringer MN, Steiner T, Davis SM (2009) Density and shape as CT predictors of intracerebral hemorrhage growth. 40:1325–31
Beigel R, Mazin I, Koifman E, Shechter M, Pres H, Shlomo N, Rosenberg N, Asher E, Matetzky S (2018) Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction. J Thromb Haemost 16:663–669. doi: 10/ghrp4n
Cahill RA, McGreal GT, Crowe BH, Ryan DA, Manning BJ, Cahill MR, Redmond HP (2005) Duration of increased bleeding tendency after cessation of aspirin therapy. 200:564–73; quiz A59-61
Camps-Renom P, Alejaldre-Monforte A, Delgado-Mederos R, Martínez-Domeño A, Prats-Sánchez L, Pascual-Goñi E, Martí-Fàbregas J (2017) Does prior antiplatelet therapy influence hematoma volume and hematoma growth following intracerebral hemorrhage? Results from a prospective study and a meta-analysis. Eur J Neurol 24:302–308. doi: 10/f9mtm8
Chan S, Brophy M, Nishimura N, Schaffer CB (2019) Aspirin treatment does not increase microhemorrhage size in young or aged mice. PLoS ONE 14:e0204295. doi: 10.1371/journal.pone.0204295
Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MTV, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S, POISE-2 Investigators (2014) Aspirin in patients undergoing noncardiac surgery. N Engl J Med 370:1494–1503. doi: 10/bcrq
Ford I (2015) Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. Therapeutic Advances in Drug Safety 6:141–150. doi: 10.1177/2042098615588085
Foreman PM, Mooney J, Ilyas A, Agee B, Vivekanandan S, Fong RP, Okor MO, Riley KO, Griessenauer CJ (2019) Antiplatelet Medication and Operative Subdural Hematomas: A Retrospective Cohort Study Evaluating Reoperation Rates. World Neurosurgery 125:e671–e677. doi: 10.1016/j.wneu.2019.01.151
van Ginneken V, Engel P, Fiebach JB, Audebert HJ, Nolte CH, Rocco A (2018) Prior antiplatelet therapy is not associated with larger hematoma volume or hematoma growth in intracerebral hemorrhage. Neurol Sci 39:745–748. doi: 10.1007/s10072-018-3255-z
Greuter L, Ullmann M, Mariani L, Guzman R, Soleman J (2019) Effect of preoperative antiplatelet or anticoagulation therapy on hemorrhagic complications in patients with traumatic brain injury undergoing craniotomy or craniectomy. Neurosurgical focus 47:E3
He G-N, Guo H-Z, Han X, Wang E-F, Zhang Y-Q (2018) Comparison of CT black hole sign and other CT features in predicting hematoma expansion in patients with ICH. J Neurol 265:1883–1890. doi: 10/gd2h8x
Jafari M, Di Napoli M, Lattanzi S, Mayer SA, Bachour S, Bershad EM, Damani R, Datta YH, Divani AA (2019) Serum magnesium level and hematoma expansion in patients with intracerebral hemorrhage. J Neurol Sci 398:39–44. doi: 10/ghthvz
Khan NI, Siddiqui FM, Goldstein JN, Cox M, Xian Y, Matsouaka RA, Heidenreich PA, Peterson ED, Bhatt DL, Fonarow GC, Schwamm LH, Smith EE (2017) Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. Stroke 48:1810–1817. doi: 10/gbktx7
Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27:1304–1305. doi: 10/c9vgn7
Leasure AC, Qureshi AI, Murthy SB, Kamel H, Goldstein JN, Woo D, Ziai WC, Hanley DF, Al-Shahi Salman R, Matouk CC, Sansing LH, Sheth KN, Falcone GJ (2019) Association of Intensive Blood Pressure Reduction With Risk of Hematoma Expansion in Patients With Deep Intracerebral Hemorrhage. JAMA Neurol. doi: 10/ghtk8r
Li Q, Li R, Zhao L-B, Yang X-M, Yang W-S, Deng L, Lv X-N, Wu G-F, Tang Z-P, Wei M, Zheng Y-N, Lv F-J, Sun X-C, Goldstein JN, Xie P (2020) Intraventricular Hemorrhage Growth: Definition, Prevalence and Association with Hematoma Expansion and Prognosis. Neurocrit Care 33:732–739. doi: 10/ghtbvp
Li Q, Liu Q-J, Yang W-S, Wang X-C, Zhao L-B, Xiong X, Li R, Cao D, Zhu D, Wei X, Xie P (2017) Island Sign: An Imaging Predictor for Early Hematoma Expansion and Poor Outcome in Patients With Intracerebral Hemorrhage. Stroke 48:3019–3025. doi: 10/gchg9m
Li Q, Warren AD, Qureshi AI, Morotti A, Falcone GJ, Sheth KN, Shoamanesh A, Dowlatshahi D, Viswanathan A, Goldstein JN (2020) Ultra-Early Blood Pressure Reduction Attenuates Hematoma Growth and Improves Outcome in Intracerebral Hemorrhage. Ann Neurol 88:388–395. doi: 10/gg4q5w
Li Q, Zhang G, Huang Y-J, Dong M-X, Lv F-J, Wei X, Chen J-J, Zhang L-J, Qin X-Y, Xie P (2015) Blend Sign on Computed Tomography: Novel and Reliable Predictor for Early Hematoma Growth in Patients With Intracerebral Hemorrhage. Stroke 46:2119–23
Luzzi S, Elia A, Del Maestro M, Morotti A, Elbabaa SK, Cavallini A, Galzio R (2019) Indication, Timing, and Surgical Treatment of Spontaneous Intracerebral Hemorrhage: Systematic Review and Proposal of a Management Algorithm. World Neurosurgery 124:e769–e778. doi: 10/ghjw7h
Maas MB, Naidech AM, Kim M, Batra A, Manno EM, Sorond FA, Prabhakaran S, Liotta EM (2018) Medication History versus Point-of-Care Platelet Activity Testing in Patients with Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases 27:1167–1173. doi: 10.1016/j.jstrokecerebrovasdis.2017.11.033
Morotti A, Arba F, Boulouis G, Charidimou A (2020) Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome: A meta-analysis. Neurology 95:632–643. doi: 10/ghgbdd
Morotti A, Boulouis G, Dowlatshahi D, Li Q, Barras CD, Delcourt C, Yu Z, Zheng J, Zhou Z, Aviv RI, Shoamanesh A, Sporns PB, Rosand J, Greenberg SM, Al-Shahi Salman R, Qureshi AI, Demchuk AM, Anderson CS, Goldstein JN, Charidimou A, International NCCT ICH Study Group (2019) Standards for Detecting, Interpreting, and Reporting Noncontrast Computed Tomographic Markers of Intracerebral Hemorrhage Expansion. Ann Neurol 86:480–492. doi: 10/gg4q5x
Morotti A, Boulouis G, Romero JM, Brouwers HB, Jessel MJ, Vashkevich A, Schwab K, Afzal MR, Cassarly C, Greenberg SM, Martin RH, Qureshi AI, Rosand J, Goldstein JN, investigators A-I and N (2017) Blood pressure reduction and noncontrast CT markers of intracerebral hemorrhage expansion. Neurology 89:548–554
Moussouttas M, Malhotra R, Fernandez L, Maltenfort M, Holowecki M, Delgado J, Lawson N, Badjatia N (2010) Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocrit Care 12:24–29. doi: 10/dpn56j
Murthy S, Roh DJ, Chatterjee A, McBee N, Parikh NS, Merkler AE, Navi BB, Falcone GJ, Sheth KN, Awad I, Hanley D, Kamel H, Ziai WC, CLEAR III, MISTIE III and VISTA-ICH Collaborators (2020) Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: an individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH. J Neurol Neurosurg Psychiatry. doi: 10/ghmqxp
Oltmann SC, Alhefdhi AY, Rajaei MH, Schneider DF, Sippel RS, Chen H (2016) Antiplatelet and Anticoagulant Medications Significantly Increase the Risk of Postoperative Hematoma: Review of over 4500 Thyroid and Parathyroid Procedures. Annals of surgical oncology 23:2874–2882
Ovesen C, Christensen AF, Krieger DW, Rosenbaum S, Havsteen I, Christensen H (2014) Time Course of Early Postadmission Hematoma Expansion in Spontaneous Intracerebral Hemorrhage. Stroke 45:994–999. doi: 10.1161/STROKEAHA.113.003608
P F, C I, R S, E P, A P, G Z (2020) Clinical practice for antiplatelet and anticoagulant therapy in neurosurgery: data from an Italian survey and summary of current recommendations - part I, antiplatelet therapy. Neurosurgical review. doi: 10.1007/s10143-019-01229-7
Rodriguez-Luna D, Rodriguez-Villatoro N, Juega JM, Boned S, Muchada M, Sanjuan E, Pagola J, Rubiera M, Ribo M, Coscojuela P, Molina CA (2018) Prehospital Systolic Blood Pressure Is Related to Intracerebral Hemorrhage Volume on Admission. Stroke 49:204–206. doi: 10.1161/STROKEAHA.117.018485
Roh DJ, Albers DJ, Magid-Bernstein J, Doyle K, Hod E, Eisenberger A, Murthy S, Witsch J, Park S, Agarwal S, Connolly ES, Elkind MSV, Claassen J (2019) Low hemoglobin and hematoma expansion after intracerebral hemorrhage. Neurology 93:e372–e380. doi: 10/ghthvp
Shimoda Y, Ohtomo S, Arai H, Okada K, Tominaga T (2017) Satellite Sign: A Poor Outcome Predictor in Intracerebral Hemorrhage. Cerebrovascular diseases (Basel, Switzerland) 44:105–112
Smith EE (2016) Risk for Intracerebral Hematoma Expansion-More Than Just the Spot Sign. JAMA Neurol 73:1401–1403. doi: 10/ghtbxg
Sprügel MI, Kuramatsu JB, Gerner ST, Sembill JA, Beuscher VD, Hagen M, Roeder SS, Lücking H, Struffert T, Dörfler A, Schwab S, Huttner HB (2018) Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation–Associated Intracerebral Hemorrhage. Stroke 49:2621–2629. doi: 10/gfk69r
Toyoda K, Koga M, Yamamoto H, Foster L, Palesch YY, Wang Y, Sakai N, Hara T, Hsu CY, Itabashi R, Sato S, Fukuda-Doi M, Steiner T, Yoon B-W, Hanley DF, Qureshi AI, ATACH-2 Trial Investigators (2019) Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage. Ann Neurol 85:105–113. doi: 10/ghtk8q
Wu J, Liu Q, Wang K, Yang J, Jiang P, Li M, Wang N, Cao Y, Ren Z, Zhang Y, Wang S (2020) Emergency surgery is an effective way to improve the outcome of severe spontaneous intracerebral hemorrhage patients on long-term oral antiplatelet therapy. Neurosurgical Review
Yamaguchi Y, Koga M, Sato S, Yamagami H, Todo K, Okuda S, Okada Y, Kimura K, Shiokawa Y, Kamiyama K, Itabashi R, Hasegawa Y, Kario K, Fujita K, Kumamoto M, Kamimura T, Ando D, Ide T, Yoshimoto T, Shiozawa M, Matsubara S, Yoshimura S, Nagatsuka K, Toyoda K, for the SAMURAI Study Investigators (2018) Early Achievement of Blood Pressure Lowering and Hematoma Growth in Acute Intracerebral Hemorrhage: Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study. Cerebrovasc Dis 46:118–124. doi: 10/gd7h7x
Yogendrakumar V, Ramsay T, Fergusson DA, Demchuk AM, Aviv RI, Rodriguez-Luna D, Molina CA, Silva Y, Dzialowski I, Kobayashi A, Boulanger J-M, Gubitz G, Srivastava P, Roy J, Kase CS, Bhatia R, Hill MD, Goldstein JN, Dowlatshahi D, for the PREDICT/Sunnybrook CTA Study Group (2020) Redefining Hematoma Expansion With the Inclusion of Intraventricular Hemorrhage Growth. Stroke 51:1120–1127. doi: 10.1161/STROKEAHA.119.027451

Table.1 Patient’s baseline characteristics according to prior ASA

Variables	nASA (N=149, 67.42%)	ASA (N=72, 32.58%)	P Value
Demographic characteristics
Gender Male Female	115 34	56 16	0.921
Age (years)	52.24±13.71	59.14±13.20	0.001
Vascular risk factors
Smoking	76	32	0.360
Alcohol	84	38	0.614
Admission high blood pressure	162.58±29.51	161.99±27.92	0.991
Admission low blood pressure	94.15±19.88	95.54±18.37	0.609
Medical history
Hypertension	139	69	0.554
Diabetes	17	18	0.009
Coronary heart disease	8	21	0.000
Ischemic stroke history	7	35	0.000
Cerebral hemorrhage history	3	7	0.010
Radiography
Side Left Right	74 75	36 36	0.963
Localization Lobar Deep	32 117	13 59	0.554
Ventricular hematoma	79	42	0.457
Subarachnoid hemorrhage	26	10	0.502
Hydrocephalus	21	17	0.079
Blend sign	51	28	0.498
Black hole sign	114	54	0.805
Satellite sign	35	15	0.658
Irregular shape	117	59	0.554
Heterogeneous hematoma density	106	58	0.134
Functional status
GCS	9.30±4.23	9.21±4.05	0.831

Abbreviations: ASA, aspirin; nASA, no aspirin; N, number; GCS, Glasgow Coma Scale.

Table.2 The association between prior ASA and HV, HG

	nASA (N=149, 67.42%)	ASA (N=72, 32.58%)	P Value
HV (mL)	45.51±29.76	32.67±25.85	0.001
HG	54	18	0.095

Abbreviations: ASA, aspirin; nASA, no aspirin; N, number; HG, Hematoma growth; HV, Hematoma volume.

Table.3 The effects of ASA on HV and HG after adjustment

	HV (mL)	HG
Odds ratio (95% confidence interval)	-10.042 (-20.376, 0.292)	0.756 (0.333, 1.718)
P value	0.057	0.504

Abbreviations: HG, Hematoma growth; HV, Hematoma volume.

Table.4 Univariate analysis for factors associated with HG

Variables	nHG (N=149, 67.42%)	HG (N=72, 32.58%)	P Value
Demographic characteristics
Gender Male Female	116 33	55 17	0.807
Age (years)	54.70±13.84	54.06±14.12	0.747
Vascular risk factors
Smoking	71	30	0.403
Alcohol	82	40	0.942
Admission high blood pressure	158.97±26.28	169.47±32.86	0.013
Admission low blood pressure	93.26±18.18	97.40±21.48	0.137
Medical history
Hypertension	140	68	0.886
Diabetes	27	8	0.185
Coronary heart disease	24	5	0.066
Ischemic stroke history	30	12	0.539
Cerebral hemorrhage History	7	3	0.859
ASA	54	18	0.097
Radiography
Side Left Right	72 77	33 39	0.728
Localization Lobar Deep	24 125	21 51	0.195
Ventricular hematoma	84	37	0.485
Subarachnoid hemorrhage	25	11	0.777
Hydrocephalus	26	12	0.021
HV (mL)	38.11±29.44	47.99±27.44	0.020
Blend sign	45	29	0.137
Black hole sign	116	58	0.645
Satellite sign	34	21	0.306
Irregular shape	125	56	0.268
Heterogeneous hematoma density	107	58	0.161
Functional status
GCS	9.82±4.26	8.12±3.72	0.005

Abbreviations: HG, Hematoma growth; nHG, no Hematoma growth; HV, Hematoma volume; ASA, aspirin; N, number; GCS, Glasgow Coma Scale.

Table.5 Multivariate analysis for factors associated with HG.

Variables	Odds ratio (95% confidence interval)	P value
ASA	0.566 (0.295, 1.086)	0.087
Admission high blood pressure	1.012 (1.002, 1.023)	0.016
GCS	0.904 (0.842, 0.971)	0.006

Abbreviations: ASA, aspirin; GCS, Glasgow Coma Scale.

PDF

Journal Publication

published 13 Oct, 2021

Read the published version in Neurosurgical Review →

Editorial decision: Major revisions
21 Jun, 2021
Reviews received at journal
26 May, 2021
Reviewers invited by journal
26 May, 2021
Editor assigned by journal
11 May, 2021
First submitted to journal
07 May, 2021

You are reading this latest preprint version

Aspirin does not Affect the Hematoma Volume and Growth in Severe Spontaneous Intracranial Hematoma

Status:

Journal Publication

Version 1

Abstract

Introduction

Materials And Methods

Results

Discussion

Conclusion

Declarations

References

Tables

Status:

Journal Publication

Version 1